Investment Rating - The investment rating for the company is "Buy" [7] Core Insights - The company's revenue and profit margins are under pressure for 2025, primarily due to public sentiment and broadcasting impacts. The company has multiple new cosmetic products in the pipeline and has received approval for two medical beauty injectables, which are key areas to monitor for future performance [2][11]. Financial Summary - Total revenue for 2025 is projected at 5,519 million RMB, a slight decrease of 0.4% year-on-year. Net profit is expected to be 1,915 million RMB, down 7% year-on-year. The gross profit margin for 2025 is estimated at 80.34%, a decrease of 1.76 percentage points compared to the previous year [4][11]. - The company anticipates a revenue increase to 6,064 million RMB in 2026, with a projected net profit of 1,914 million RMB, remaining stable year-on-year [4][11]. - The company's PE ratio is expected to decrease from 22.89 in 2024 to 17.12 in 2025, indicating a more attractive valuation over time [4][11]. Brand and Product Development - The main brand, Kefu Mei, is experiencing a slight decline due to public sentiment and broadcasting efficiency issues. In 2025, Kefu Mei's revenue is expected to be 4,470 million RMB, a decrease of 2% year-on-year, while the Keli Jin brand is projected to grow by 9% to 917 million RMB [11]. - The company is focusing on enhancing its medical beauty business, with new products expected to launch in 2026, including collagen repair series and other functional skincare products [11].